1. HBW Insight
  2. >>Leadership

Drug Reviewers And Legal Staff Among Those Called Back to US FDA, But Why?

 
• By Sarah Karlin-Smith

Like the layoffs, the reason for the recalls of some laid off CDER and Office of Chief Counsel staff remains unclear.

US Food and Drug Administration
The FDA is recalling more staff just one week after instituting layoffs. (Shutterstock)
Key Takeaways
  • Staff in CDER and the Office of Chief Counsel are among those getting their jobs back a week after mass layoffs of FDA probationary employees, sources told the Pink Sheet.
  • Not all of the laid off staff in CDER were expected to be brought back, while the agency's device center seems to have recalled nearly all affected staffers.
  • Even with many positions restored, close FDA allies still worry that the situation could cause long-term harm to agency recruiting and retention.

Some of the approximately 300 Center for Drug Evaluation and Research employees who were dismissed are being reinstated, a former senior FDA official tells Pink Sheet,

Most of the employees

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

In Blistering Criticism, Health Subcommittee Democrat Warns Of Kennedy’s ‘Toxic Brew’ Plans

 
• By Malcolm Spicer

Trump’s first-term public health appointees “were serious people doing serious work in a bipartisan nature,” but HHS Secretary Robert F. Kennedy and other current presidential advisors “are not serious people,” says Massachusetts’ Jake Auchincloss.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 
• By Malcolm Spicer

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

Commissioner Makary Outlines Expectations For US FDA: ‘Challenge Deeply Held Assumptions’

 
• By Malcolm Spicer

“It was a little hard to begin after the change or the reduction in force. We're doing everything we can to do an assessment, restore some services of individuals, and also try to rebuild the culture, because it is a great culture,” says FDA Commissioner Martin Makary during FDLI conference.

More from HBW Insight

In Blistering Criticism, Health Subcommittee Democrat Warns Of Kennedy’s ‘Toxic Brew’ Plans

 
• By Malcolm Spicer

Trump’s first-term public health appointees “were serious people doing serious work in a bipartisan nature,” but HHS Secretary Robert F. Kennedy and other current presidential advisors “are not serious people,” says Massachusetts’ Jake Auchincloss.

Green Guides Update, FTC Enforcement In ‘Deregulatory’ Environment – BBB National Programs’ Engle During IBA Conference

 
• By Eileen Francis

The FTC’s Green Guides proposed update was expected by the end of the Biden Administration and there’s no indication it will be unveiled soon, says Mary Engle, BBB National Programs Exec VP, Policy. She also discussed the importance of industry self-regulation of artificial intelligence.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 
• By Malcolm Spicer

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.